drugset / Trial / NCT03915678
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Phase 2
Recruiting
247 enrolled
Institut Bergonié
Eikon Therapeutics · collabNational Cancer Institute, France · collabRoche Pharma AG · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
Timeline
- Start
- 2021-03-31
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Resiquimod | Small molecule | — | Intravenous |